

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	INTEGRAL DIAGNOSTICS LIMITED
ABN	55 130 832 816

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Ian Kadish
Date of last notice	29 August 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	20 September 2023
No. of securities held prior to change	539,441 fully paid ordinary shares 184,616 Rights approved by Shareholders 28 Oct 2020 157,371 Rights approved by Shareholders 5 Nov 2021 <u>241,591</u> Rights approved by Shareholders 4 Nov 2022 583,578 Rights
Class	Performance Rights - STI (STI Rights)
Number acquired	26,035 Performance Rights - STI
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	<p><u>Ordinary Shares</u> 539,441 fully paid ordinary shares</p> <p><u>Performance Rights (Rights) relating to LTI Plan</u> 184,616 Rights approved by Shareholders 28 Oct 2020 157,371 Rights approved by Shareholders 5 Nov 2021 <u>241,591</u> Rights approved by Shareholders 4 Nov 2022 583,578 Rights</p> <p><u>Performance Rights – STI (STI Rights) relating to STI Plan</u> 26,035 STI Rights approved by shareholders 4 Nov 2022</p>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of STI Performance Rights to CEO pursuant to the Company's Equity Incentive Plan as approved by shareholders on 4 November 2022.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.